ICER to assess treatment for vasomotor symptoms associated with menopause

ICER

1 June 2022 - Report will be subject of Midwest CEPAC meeting in December 2022; draft scoping document open to public comment until 21 June 2022.

The ICER announced today that it will assess the comparative clinical effectiveness and value of fezolinetant (Astellas) for the vasomotor symptoms associated with menopause.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder